Pappachan JM, Viswanath AK. Metabolic surgery: A paradigm shift in type 2 diabetes management. World J Diabetes 2015; 6(8): 990-998 [PMID: 26240695 DOI: 10.4239/wjd.v6.i8.990]
Corresponding Author of This Article
Dr. Joseph M Pappachan, MD, MRCP (London), Department of Endocrinology and Diabetes, New Cross Hospital, the Royal Wolverhampton Hospital NHS Trust, Wolverhampton Road, Wolverhampton WV10 0QP, United Kingdom. drpappachan@yahoo.co.in
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Jul 25, 2015; 6(8): 990-998 Published online Jul 25, 2015. doi: 10.4239/wjd.v6.i8.990
Metabolic surgery: A paradigm shift in type 2 diabetes management
Joseph M Pappachan, Ananth K Viswanath
Joseph M Pappachan, Ananth K Viswanath, Department of Endocrinology and Diabetes, New Cross Hospital, the Royal Wolverhampton Hospital NHS Trust, Wolverhampton WV10 0QP, United Kingdom
Author contributions: Viswanath AK conceived the idea; Pappachan JM wrote the initial draft of the paper; both authors contributed to literature search and final preparation of the manuscript.
Conflict-of-interest statement: Ananth K Viswanath received lecture fees from MSD, NovoNordisk, Takeda, Eilly Lilly, Jansen and sponsorship from NovoNordisk, Takeda, Novartis and Jansen to attend international conferences. Joseph M Pappachan has no conflicts of interest to declare.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Joseph M Pappachan, MD, MRCP (London), Department of Endocrinology and Diabetes, New Cross Hospital, the Royal Wolverhampton Hospital NHS Trust, Wolverhampton Road, Wolverhampton WV10 0QP, United Kingdom. drpappachan@yahoo.co.in
Telephone: +44-1922-721172 Fax: +44-1922-721172
Received: April 12, 2015 Peer-review started: April 15, 2015 First decision: April 27, 2015 Revised: April 30, 2015 Accepted: May 27, 2015 Article in press: May 28, 2015 Published online: July 25, 2015 Processing time: 113 Days and 17.8 Hours
Core Tip
Core tip: Metabolic surgery or bariatric surgery has revolutionised the 21st century management of type 2 diabetes mellitus (T2DM) in obese patients. Marked reduction of body weight following the bariatric procedures results in improvement or remission of T2DM in a significant number of patients along with improvement of other diseases associated with obesity such as hypertension, obstructive sleep apnoea, osteoarthritis and non-alcoholic fatty liver disease. Uncertainty exists about the long-term outcomes in terms of diabetes relapse, nutritional and psychosocial complications. However, the marked benefits of metabolic surgery outweigh the risks related to the procedure that has resulted in a major paradigm shift in the management of obese population with T2DM in recent years which is the topic of discussion of this paper.
